Last 7 days
-6.3%
Last 30 days
6.0%
Last 90 days
-16.8%
Trailing 12 Months
-0.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 115.9B | 26.2B | -9.16% | -12.25% | 14.64 | 4.43 | -0.48% | 38.34% |
GILD | 96.2B | 27.0B | -7.94% | 24.63% | 17.23 | 3.56 | -1.56% | 23.65% |
MRNA | 48.5B | 15.1B | -3.43% | -7.04% | 10.13 | 3.22 | -33.37% | -67.32% |
BIIB | 43.1B | 10.1B | 3.69% | 46.24% | 13.77 | 4.27 | -6.61% | 115.98% |
MID-CAP | ||||||||
NBIX | 8.9B | 1.6B | -11.20% | 1.54% | 138.97 | 5.56 | 32.38% | -10.36% |
DNLI | 4.1B | - | 22.94% | 24.01% | -11.06 | 37.77 | 122.90% | -29.67% |
BEAM | 2.4B | 76.7M | 5.96% | -0.58% | -7.62 | 31.42 | 41.73% | -32.75% |
BBIO | 2.2B | 107.9M | -3.78% | 107.70% | -4.55 | 20.44 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.6B | 119.0M | 22.46% | 21.04% | -5.77 | 13.53 | -69.61% | -584.39% |
REPL | 1.1B | 10.0M | 16.71% | 38.03% | -6.34 | 110.4 | 215.65% | -47.65% |
NVAX | 622.2M | - | -4.25% | -84.68% | -0.54 | 0.31 | 72.89% | 12.32% |
FATE | 503.7M | 136.9M | -11.86% | -77.13% | -2.14 | 3.68 | 116.83% | -0.93% |
SGMO | 210.2M | 241.0M | -21.74% | -64.41% | -1.65 | 0.87 | 113.96% | 27.87% |
VXRT | 162.7M | 697.0K | 67.22% | -64.71% | -1.51 | 233.45 | 47.98% | -35.48% |
IBIO | 9.3M | - | -31.01% | -87.63% | -0.12 | 3.21 | 0.51% | -129.47% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Revenue | 25.9% | 76,696,000 | 60,920,000 | 58,651,000 | 56,382,000 | 54,113,000 |
Operating Expenses | 9.6% | 437,878,000 | 399,399,000 | 404,930,000 | 368,225,000 | 328,587,000 |
S&GA Expenses | 4.8% | 92,048,000 | 87,805,000 | 82,896,000 | 76,855,000 | 66,196,000 |
R&D Expenses | 11.0% | 345,830,000 | 311,594,000 | 322,034,000 | 291,370,000 | 262,391,000 |
EBITDA | 12.1% | -245,655,000 | -279,483,000 | - | - | - |
EBITDA Margin | 15.4% | -4.03 | -4.77 | - | - | - |
Earnings Before Taxes | 11.1% | -260,178,000 | -292,744,000 | - | - | - |
EBT Margin | 14.4% | -4.27 | -4.99 | - | - | - |
Interest Expenses | -13.6% | 325,000 | 376,000 | 424,000 | 474,000 | 521,000 |
Net Income | -9.4% | -316,334,000 | -289,088,000 | -315,446,000 | -233,989,000 | -238,292,000 |
Net Income Margin | 11.8% | -4.75 | -5.38 | -4.51 | - | - |
Free Cahsflow | -166.9% | -26,424,000 | 39,489,000 | 122,999,000 | 148,208,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -0.7% | 1,332 | 1,342 | 1,350 | 1,418 | 1,453 |
Current Assets | -0.9% | 1,083 | 1,093 | 1,109 | 1,180 | 1,239 |
Cash Equivalents | 11.5% | 260 | 233 | 157 | 266 | 297 |
Net PPE | 5.4% | 122 | 116 | 111 | 106 | 94.00 |
Liabilities | -6.1% | 571 | 608 | 636 | 618 | 624 |
Current Liabilities | -1.6% | 220 | 224 | 239 | 212 | 219 |
Shareholder's Equity | 3.8% | 762 | 733 | 714 | 800 | 829 |
Retained Earnings | -4.9% | -1,153 | -1,100 | -1,000 | -909 | -837 |
Additional Paid-In Capital | 6.9% | 1,915 | 1,793 | 1,737 | 1,713 | 1,669 |
Accumulated Depreciation | 15.3% | 26.00 | 23.00 | 19.00 | - | - |
Shares Outstanding | 4.4% | 74.00 | 71.00 | 70.00 | 70.00 | 70.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -1457.4% | -305 | 23.00 | 94.00 | 171 | 191 |
Share Based Compensation | 7.0% | 90.00 | 84.00 | 77.00 | 68.00 | 57.00 |
Cashflow From Investing | 122.0% | 101 | -461 | -652 | -539 | -551 |
Cashflow From Financing | 38.3% | 154 | 112 | 101 | 420 | 559 |
66.5%
66.5%
50.8%
Y-axis is the maximum loss one would have experienced if Beam Therapeutics was unfortunately bought at previous high price.
-7.0%
10%
FIve years rolling returns for Beam Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | Capital Impact Advisors, LLC | added | 3.66 | -89,570 | 385,812 | 0.47% |
2023-05-22 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | new | - | 1,832,000 | 1,832,000 | 0.70% |
2023-05-22 | AMERIPRISE FINANCIAL INC | sold off | -100 | -287,000 | - | -% |
2023-05-18 | INTERNATIONAL BIOTECHNOLOGY TRUST PLC | unchanged | - | -201,160 | 717,925 | 0.20% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -18.62 | -786,000 | 1,381,000 | -% |
2023-05-18 | JPMORGAN CHASE & CO | reduced | -2.6 | -6,884,690 | 22,111,300 | -% |
2023-05-17 | Advisory Services Network, LLC | unchanged | - | -1,103 | 3,981 | -% |
2023-05-17 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -34.12 | -185,924 | 219,016 | -% |
2023-05-16 | Ancora Advisors, LLC | unchanged | - | -469 | 1,531 | -% |
2023-05-16 | CHILTON CAPITAL MANAGEMENT LLC | new | - | 3,828 | 3,828 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 17, 2023 | temasek holdings (private) ltd | 5.0% | 3,644,573 | SC 13G | |
Feb 14, 2023 | farallon capital partners, l.p. | 0.0% | 0 | SC 13G/A | |
Feb 10, 2023 | temasek holdings (private) ltd | 4.1% | 2,878,297 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.90% | 6,273,630 | SC 13G/A | |
Feb 02, 2023 | blackrock inc. | 7.4% | 5,238,280 | SC 13G/A | |
Jul 14, 2022 | farallon capital partners, l.p. | 0.4% | 276,948 | SC 13G | |
Feb 14, 2022 | arch venture fund ix, l.p. | 8.6% | 5,843,039 | SC 13G/A | |
Feb 14, 2022 | redmile group, llc | 2.8% | 1,885,850 | SC 13G/A | |
Feb 14, 2022 | temasek holdings (private) ltd | 5.8% | 3,959,212 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
May 10, 2023 | 10-Q | Quarterly Report | |
May 10, 2023 | 424B5 | Prospectus Filed | |
May 10, 2023 | 8-K | Current Report | |
May 10, 2023 | 8-K | Current Report | |
Apr 21, 2023 | ARS | ARS | |
Apr 21, 2023 | DEF 14A | DEF 14A | |
Apr 21, 2023 | DEFA14A | DEFA14A | |
Apr 19, 2023 | 4/A | Insider Trading | |
Apr 05, 2023 | 4 | Insider Trading | |
Apr 05, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-04-04 | Simon Amy | sold | -346,115 | 29.6993 | -11,654 | chief medical officer |
2023-04-04 | Evans John M. | sold | -188,904 | 29.0935 | -6,493 | ceo |
2023-04-04 | Bellon Christine | sold | -33,777 | 29.0931 | -1,161 | chief legal officer |
2023-04-04 | Burrell Terry-Ann | sold | -63,597 | 29.0931 | -2,186 | chief financial officer |
2023-04-04 | Ciaramella Giuseppe | sold | -51,028 | 29.0929 | -1,754 | president & cso |
2023-04-03 | Simon Amy | sold | -134,728 | 30.31 | -4,445 | chief medical officer |
2023-04-03 | Ciaramella Giuseppe | sold | -58,134 | 30.31 | -1,918 | president & cso |
2023-04-03 | Burrell Terry-Ann | sold | -74,380 | 30.31 | -2,454 | chief financial officer |
2023-04-03 | Bellon Christine | sold | -28,218 | 30.31 | -931 | chief legal officer |
2023-04-03 | Evans John M. | sold | -156,430 | 30.31 | -5,161 | ceo |
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
License and collaboration revenue | $ 24,208 | $ 8,432 |
Revenue, Product and Service [Extensible List] | us-gaap:LicenseMember | us-gaap:LicenseMember |
Operating expenses: | ||
Research and development | $ 99,646 | $ 65,410 |
General and administrative | 23,490 | 19,247 |
Total operating expenses | 123,136 | 84,657 |
Loss from operations | (98,928) | (76,225) |
Other income (expense): | ||
Change in fair value of derivative liabilities | 5,600 | 13,600 |
Change in fair value of non-controlling equity investments | (12,797) | (7,685) |
Change in fair value of contingent consideration liabilities | (296) | 452 |
Interest and other income (expense), net | 9,961 | 644 |
Total other income (expense) | 2,468 | 7,011 |
Net loss | (96,460) | (69,214) |
Unrealized gain (loss) on marketable securities | 1,665 | (2,659) |
Comprehensive loss | $ (94,795) | $ (71,873) |
Net loss per common share, basic | $ (1.33) | $ (1.01) |
Net loss per common share, diluted | $ (1.33) | $ (1.01) |
Weighted - average common shares outstanding, basic | 72,273,829 | 68,703,864 |
Weighted - average common shares outstanding, diluted | 72,273,829 | 68,703,864 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 249,771 | $ 232,767 |
Marketable securities | 809,700 | 845,367 |
Prepaid expenses and other current assets | 23,560 | 14,762 |
Total current assets | 1,083,031 | 1,092,896 |
Property and equipment, net | 121,822 | 115,620 |
Restricted cash | 9,802 | 12,754 |
Operating lease right-of-use assets | 116,159 | 118,513 |
Other assets | 1,538 | 1,931 |
Total assets | 1,332,352 | 1,341,714 |
Current liabilities: | ||
Accounts payable | 14,063 | 9,029 |
Accrued expenses and other current liabilities | 37,847 | 48,059 |
Derivative liabilities | 12,700 | 18,300 |
Current portion of deferred revenue | 142,737 | 135,974 |
Current portion of lease liability | 11,157 | 10,380 |
Current portion of equipment financing liability | 1,421 | 1,853 |
Total current liabilities | 219,925 | 223,595 |
Long-term lease liability | 165,298 | 168,625 |
Long-term equipment financing liability | 983 | 1,154 |
Contingent consideration liabilities | 12,759 | 12,463 |
Long-term portion of deferred revenue | 171,708 | 202,179 |
Other liabilities | 173 | 224 |
Total liabilities | 570,846 | 608,240 |
Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements) | ||
Stockholders’ equity: | ||
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2023 and December 31, 2022 , respectively | ||
Common stock, $0.01 par value; 250,000,000 shares authorized, 74,435,392 and 71,277,339 issued and outstanding at March 31,2023 and December 31, 2022 respectively | 744 | 712 |
Additional paid-in capital | 1,915,349 | 1,792,554 |
Accumulated other comprehensive (loss) income | (765) | (2,430) |
Accumulated deficit | (1,153,822) | (1,057,362) |
Total stockholders' equity | 761,506 | 733,474 |
Total liabilities and stockholders' equity | $ 1,332,352 | $ 1,341,714 |